Hodi FS - Search Results

1

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD. Sridharan V, et al. Among authors: hodi fs. Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5. Br J Cancer. 2016. PMID: 27380136 Free PMC article.

2

Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.

Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Sittler T, et al. Among authors: hodi fs. Clin Cancer Res. 2008 Jun 15;14(12):3896-905. doi: 10.1158/1078-0432.CCR-07-4782. Clin Cancer Res. 2008. PMID: 18559611

3

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Jiang X, et al. Among authors: hodi fs. Clin Cancer Res. 2008 Dec 1;14(23):7726-32. doi: 10.1158/1078-0432.CCR-08-1144. Clin Cancer Res. 2008. PMID: 19047099

4

Modulation of T-cell activation by malignant melanoma initiating cells.

Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Schatton T, et al. Among authors: hodi fs. Cancer Res. 2010 Jan 15;70(2):697-708. doi: 10.1158/0008-5472.CAN-09-1592. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068175 Free PMC article.

5

Active immunotherapy induces antibody responses that target tumor angiogenesis.

Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Schoenfeld J, et al. Among authors: hodi fs. Cancer Res. 2010 Dec 15;70(24):10150-60. doi: 10.1158/0008-5472.CAN-10-1852. Cancer Res. 2010. PMID: 21159637 Free PMC article.

6

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.

Zhou J, Yuen NK, Zhan Q, Velazquez EF, Murphy GF, Giobbie-Hurder A, Hodi FS. Zhou J, et al. Among authors: hodi fs. Cancer Immunol Immunother. 2012 May;61(5):655-65. doi: 10.1007/s00262-011-1124-1. Epub 2011 Oct 28. Cancer Immunol Immunother. 2012. PMID: 22033581 Free PMC article.

7

c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.

Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M, Hodi FS. Wu X, et al. Among authors: hodi fs. Melanoma Res. 2012 Apr;22(2):123-32. doi: 10.1097/CMR.0b013e3283507ffd. Melanoma Res. 2012. PMID: 22343486

8

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. Jiang X, et al. Among authors: hodi fs. Clin Cancer Res. 2013 Feb 1;19(3):598-609. doi: 10.1158/1078-0432.CCR-12-2731. Epub 2012 Oct 24. Clin Cancer Res. 2013. PMID: 23095323

9

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Luke JJ, et al. Among authors: hodi fs. Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2. Cancer. 2013. PMID: 23913718 Free PMC article.

10

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.

Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB, Wolchok JD, Hodi FS. Yuan J, et al. Among authors: hodi fs. Cancer Immunol Res. 2014 Feb;2(2):127-32. doi: 10.1158/2326-6066.CIR-13-0163. Cancer Immunol Res. 2014. PMID: 24778276 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

391 results

Search Page